Citadel Advisors
RVLP

Citadel Advisors’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Citadel Advisors’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-200
Closed -$112 – 15449
2023
Q2 		$112 Hold
200
– – ﹤0.01% 14218
2023
Q1 		$228 Sell
200
-1,800
-90% -$2.16K ﹤0.01% 14543
2022
Q4 		$2.24K Sell
2,000
-49,400
-96% -$78.7K ﹤0.01% 14362
2022
Q3 		$108K Buy
+51,400
New +$99.9K ﹤0.01% 11024

Other funds holding RVLP

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
TAM
Titleist Asset Management San Antonio, Texas $1.49B AUM 22.27% 1-Year Est. Return

Citadel Advisors's RVLP Position: Q3 2023 in Review

Citadel Advisors sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q3 2023, closing a stake of 51,693 shares — an estimated $29K sold.

Citadel Advisors first reported a position in RVLP in Q2 2019 and held it in 8 quarters. The position peaked at $190K in Q1 2020. 32 funds tracked by Wall St. Rank hold RVLP as of Q3 2023.

  • Citadel Advisors reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 51,693 RVL Pharmaceuticals plc Ordinary Shares shares in Q3 2023, an estimated $29K.
  • Citadel Advisors first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q2 2019 and held it in 8 quarters.
  • Citadel Advisors's RVL Pharmaceuticals plc Ordinary Shares position peaked at $190K in Q1 2020.
  • 32 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.